Yoko Tsukita
YOU?
Author Swipe
View article: Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings
Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings Open
The primary endpoint was unmet; however, lenvatinib demonstrated relatively favorable efficacy and safety in patients with previously treated thymic carcinoma, even in real-world clinical practice involving diverse populations.
View article: Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901
Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901 Open
The emergence of immune checkpoint inhibitors (ICIs) has revolutionized standard therapies for non-small cell lung cancer (NSCLC) [...]
View article: Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902 Open
View article: Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile
Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile Open
Metabolomic analysis may be useful for the diagnosis and treatment of lung cancer and may provide clues for new therapeutic strategies. PC ae C42:2, SM C24:1, and lysoPC a C18:2 can serve as predictive biomarkers for monitoring the therape…
View article: The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) Open
UMIN000038683.
View article: Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC Open
BACKGROUND Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable. OBJECTIVE This study aims to seek predictors of c…
View article: Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer Open
Importance Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non–small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on I…
View article: Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas Open
View article: Durvalumab after chemoradiotherapy in non‐small cell lung cancer with <scp>EGFR</scp> mutation: A real‐world study (<scp>HOT2101</scp>)
Durvalumab after chemoradiotherapy in non‐small cell lung cancer with <span>EGFR</span> mutation: A real‐world study (<span>HOT2101</span>) Open
Durvalumab has been administered to patients with unresectable stage III non‐small cell lung cancer (NSCLC). However, it remains unclear whether durvalumab benefits these patients with epidermal growth factor receptor (EGFR) mutation. We c…
View article: Durvalumab with Etoposide and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer and Interstitial Lung Disease: A Multicenter, Open-Label Prospective Trial
Durvalumab with Etoposide and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer and Interstitial Lung Disease: A Multicenter, Open-Label Prospective Trial Open
View article: Histological and Genetic Features and Therapeutic Responses of Lung Cancers Explored Via the Global Analysis of Their Metabolome Profile
Histological and Genetic Features and Therapeutic Responses of Lung Cancers Explored Via the Global Analysis of Their Metabolome Profile Open
View article: P2.09-23 A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study)
P2.09-23 A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study) Open
View article: P2.09-20 Updated Data of Osimertinib Rechallenge after Pneumonitis; A Multicenter Retrospective Cohort Study
P2.09-20 Updated Data of Osimertinib Rechallenge after Pneumonitis; A Multicenter Retrospective Cohort Study Open
View article: IgA Vasculitis during Atezolizumab Treatment
IgA Vasculitis during Atezolizumab Treatment Open
A 66-year-old man with stage IVA small-cell carcinoma received first-line treatment with carboplatin (AUC=5), etoposide (100 mg/m 2 ), and atezolizumab (1,200 mg/body).After 82 days of the initial treatment, the patient developed multiple …
View article: Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment Open
Antibody titers after the second vaccination were lower in cancer patients than those in healthy individuals. Our findings provide essential information for understanding the benefits and necessity of additional vaccination to prevent SARS…
View article: Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer
Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer Open
Background and purpose The purpose of this prospective study was to investigate changes in longitudinal parameters after stereotactic radiotherapy for lung cancer and to identify possible pretreatment factors related to radiation-induced l…
View article: Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy Open
Rational Corticosteroid therapy plays a key role in the treatment of COVID-19 patients with respiratory failure. However, a rebound phenomenon after steroid cessation rarely occurs. Here, we investigated the clinical features of patients w…
View article: The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study Open
View article: Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study
Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study Open
Purpose: A phase II study carried out to assess the efficacy of a risk-adapted strategy of stereotactic radiosurgery (SRS) for lung cancer. The primary endpoint was 3-year local recurrence, and the secondary endpoints were overall survival…
View article: Decreased expression of airway epithelial Axl is associated with eosinophilic inflammation in severe asthma
Decreased expression of airway epithelial Axl is associated with eosinophilic inflammation in severe asthma Open
Axl kinase expressed by basal cells may suppress excessive eosinophilic inflammation via inhibition of GM-CSF in the airway. Axl reduction has clinical implications for the pathogenesis of severe asthma.
View article: Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice Open
Background In clinical practice, the effect of durvalumab and radiation pneumonitis (RP) on survival after intensity-modulated radiotherapy (IMRT) is not fully understood. The purpose of this retrospective study was to investigate factors …
View article: First-line therapy in non-small cell lung cancer patients with <i>EGFR</i> activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study
First-line therapy in non-small cell lung cancer patients with <i>EGFR</i> activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study Open
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been established as the standard first-line treatment for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an EGFR activating m…
View article: A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining
A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining Open
View article: Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study Open
Background Owing to the rarity of this tumor, there is limited information about second-line chemotherapy for patients with previously treated advanced thymic carcinoma. Material and Methods We performed a multi-institutional, retrospectiv…
View article: Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas Open
View article: Additional file 2: of Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
Additional file 2: of Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas Open
Table S1. 935 genes positively correlating AXL mRNA expression in a NSCLC biobank (GSE accession number, GSE42127). Table S2. 137 genes negatively correlating AXL mRNA expression in a NSCLC biobank (GSE accession number, GSE42127). Table S…
View article: Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations
Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations Open
Recent clinical trials of non‐small cell lung cancer with immune checkpoint inhibitors revealed that patients with epidermal growth factor receptor ( EGFR ) mutations had more unfavorable outcomes compared with those with wild‐type EGFR . …
View article: Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5
Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5 Open
Tumor-associated blood vessels and lymphatics are abnormal and dysfunctional. These are hallmarks of the tumor microenvironment, which has an immunosuppressive nature, such as through hypoxia. Treatment with anti-death receptor5 (DR5) mono…
View article: Aspiration pneumonia induces muscle atrophy in the respiratory, skeletal, and swallowing systems
Aspiration pneumonia induces muscle atrophy in the respiratory, skeletal, and swallowing systems Open
Background Repetition of the onset of aspiration pneumonia in aged patients is common and causes chronic inflammation. The inflammation induces proinflammatory cytokine production and atrophy in the muscles. The proinflammatory cytokines i…
View article: A Case of Infection of <i>Chlamydophila Pneumoniae</i> with ARDS
A Case of Infection of <i>Chlamydophila Pneumoniae</i> with ARDS Open
47歳，女性．発熱を主訴に入院し，各種検査で原因不明であったが，抗菌薬が開始された．第2病日に播種性血管内凝固症候群（disseminated intravascular coagulation：DIC），第4病日に低酸素血症を呈し，胸部単純CTで両側性の浸潤影・すりガラス影を認めた．当科転科後，ミノサイクリンを開始し，酸素化の改善が得られた．約2週間後のChlamydophila pneumoniae（C. pneumoniae）IgM抗体が7.17と上昇し，C. pne…